These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15766724)

  • 1. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous and BSE-prion-seeded amyloid formation of full length recombinant bovine prion protein.
    Panza G; Stöhr J; Dumpitak C; Papathanassiou D; Weiss J; Riesner D; Willbold D; Birkmann E
    Biochem Biophys Res Commun; 2008 Sep; 373(4):493-7. PubMed ID: 18585368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
    Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
    J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
    Touil F; Pratt S; Mutter R; Chen B
    J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
    Surewicz WK; Jones EM; Apetri AC
    Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photo-induced crosslinking of prion protein oligomers and prions.
    Piening N; Weber P; Högen T; Beekes M; Kretzschmar H; Giese A
    Amyloid; 2006 Jun; 13(2):67-77. PubMed ID: 16911960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro self-propagation of recombinant PrPSc-like conformation generated in the yeast cytoplasm.
    Yang W; Yang H; Tien P
    FEBS Lett; 2006 Jul; 580(17):4231-5. PubMed ID: 16831424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into the interaction between prion protein and nucleic acid.
    Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
    Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
    Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
    J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring prion protein stability by NMR.
    Julien O; Graether SP; Sykes BD
    J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
    Baskakov IV; Bocharova OV
    Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection, quantification, and glycotyping of prion protein in specifically activated enzyme-linked immunosorbent assay plates.
    Triantaphyllidou IE; Sklaviadis T; Vynios DH
    Anal Biochem; 2006 Dec; 359(2):176-82. PubMed ID: 17092479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of possible prion protein self-interaction domains using peptide arrays.
    Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
    BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot spots in prion protein for pathogenic conversion.
    Kuwata K; Nishida N; Matsumoto T; Kamatari YO; Hosokawa-Muto J; Kodama K; Nakamura HK; Kimura K; Kawasaki M; Takakura Y; Shirabe S; Takata J; Kataoka Y; Katamine S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):11921-6. PubMed ID: 17616582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.